The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded Godx Inc. a $1.8 million definitive contract under the Rapid, Low-Cost, Point-of-Care Diagnostic to Detect Enteric Pathogens and Antibiotic Resistance program. The firm fixed price contract runs from July 1, 2022 through June 30, 2026 and tasks Godx Inc. with developing a point-of-care diagnostic test to rapidly detect enteric pathogens and antibiotic resistance to support public health efforts.
Generated 11/27/23, 8:44 PM